目前还没有研究使用扩展前列腺指数综合问卷-26（EPIC-26）来研究外部束射线治疗（EBRT，3DCRT / IMRT）与高剂量放射治疗（BT+，3DCRT / IMRT）在治疗后的领域总结得分（DSS）和生活质量（QoL）之间的长期关联。在这项横断面研究中，我们比较了BT+与EBRT治疗后的长期不良反应和生活质量。过去的至少5年内在奥斯陆大学医院接受BT+治疗的前列腺癌幸存者（2004年至2010年，n = 259）或接受EBRT治疗的病例（多中心队列，2009年至2010年，n = 99）完成了包含EPIC-26、12-项简表和与共病/社会地位有关的问题的问卷。结果以QoL的DSS和身体/精神综合得分（PCS / MCS）呈现。回归分析首先探讨了治疗模式与DSS之间的关联，其次探讨了DSS对QoL的影响。我们估计了存在重大/中度问题的患者比例。临床相关性根据已发表的最小重要差异的最低限度设定。P值<0.05被认为具有统计学意义。在多元回归分析中，只有尿失禁的DSS在BT+组比EBRT组显著高（90 vs. 83，P < 0.05），且在临床上具有重要意义。BT+组的中重度尿道或肠道问题的患者数量减少了一半（P < 0.05）。BT+组患有受损PCS（评分< 45）的患者比EBRT组少（P = 0.02）。回归分析显示，肠道和尿道刺激/梗阻DSS降低预测了PCS和MCS的恶化（分别为P < 0.001和P = 0.007）。与EBRT相比，通过BT进行剂量递增的放射治疗不会对长期不良反应、重大问题或QoL产生负面影响。需要进行未来的随机研究，使用改进的EBRT技术。

There are few studies utilizing the Expanded Prostate Index Composite questionnaire-26 (EPIC-26) questionnaire to examine the long-term association between Domain Summary Scores (DSSs) and Quality of Life (QoL) after External Beam Radiation Therapy (EBRT, 3DCRT [3D conventional radiotherapy]/IMRT [intensity modulated radiation therapy]) versus EBRT combined with High-Dose-Rate Brachytherapy (BT+, 3DCRT [3D conventional radiotherapy]/IMRT). In this cross-sectional study we compare long-term adverse effects and QoL after BT+ with EBRT.Prostate Cancer Survivors who at least 5 years previously, had undergone BT+ at Oslo University Hospital between 2004 and 2010 (n = 259) or EBRT (multicentre cohort) between 2009 and 2010 (n = 99) completed a questionnaire containing EPIC-26, Short Form-12 and questions regarding comorbidity/social status. Results were presented as DSSs and Physical/Mental Composite Scores of QoL (PCS/MCS). Regression analyses explored firstly the associations between treatment modality and DSSs and secondly the impact of DSSs on QoL. We estimated the proportions of patients with big/moderate problems. Clinical relevance was set according to the lowest limit of published Minimal Important Differences. P-values <0.05 were considered statistically significant.In multivariate analysis, only the urinary incontinence DSS remained statistically (P < 0.05) and clinically significantly greater after BT+ than EBRT (90 vs. 83). The number of men with moderate/big urinary or bowel problems was halved after BT+ (P < 0.05). The number of patients with impaired PCS (score < 45) were lower in the BT+ group than the EBRT group (P = 0.02). Regression analysis showed that decreasing levels of bowel and urinary irritation/obstructive DSSs predicted worsening of PCS (P < 0.001) and MCS (P = 0.007), respectively.Dose-escalated radiotherapy by BT did not negatively impact long-term adverse effects, substantial problems or QoL compared with EBRT. Future randomised studies using improved EBRT techniques are needed.